Live symbol workspace

GSK market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $51.30

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$48.73

Resistance

$53.87

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$51.30

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

— 0.0 pts vs previous week

Avg confidence across 6 calls in the last 7 days

What sources say

Neutral 1 article

Earnings tonic boosts FTSE 100 as oil falls back

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

GSK News Intelligence (4 articles)

AI-curated news influencing GSK price, sentiment, and trend

Explore All GSK News with AI Analysis

Economy

3 weeks ago

Earnings tonic boosts FTSE 100 as oil falls back

Well-received earnings from Unilever, Croda and GSK spurred gains on the blue-chip FTSE 100.

Impact on GSK: Neutral market sentiment indicated

Financial market analysis indicating neutral sentiment based on current trends. Medium (50%)

View full analysis →

Yahoo Finance 50% confidence

Economy

1 month, 3 weeks ago

Africa CDC Calls for More Ebola Funding

As Ebola cases rise in the Democratic Republic of Congo and Uganda, Africa CDC's Director General Jean Kaseya says more …

Impact on GSK: The news may lead to increased investment in healthcare and pharmaceutical stocks, …

The Africa CDC is calling for increased funding to combat the rising Ebola cases in … Medium (50%)

View full analysis →

Bloomberg 50% confidence

Economy

2 months, 1 week ago

GSK Agrees to Buy Nuvalent for $10.6 Billion

GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for …

Impact on GSK: The acquisition is likely to boost GSK's stock price, with potential positive …

GSK has agreed to acquire Nuvalent for $10.6 billion, expanding its oncology portfolio with lung … High (80%)

View full analysis →

Bloomberg 80% confidence

Global Markets & Finance

2 months, 1 week ago

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity has enjoyed an upswing this year

Impact on GSK: The potential acquisition of Nuvalent by GSK for over $9 billion could …

GSK is in talks to acquire cancer biotech Nuvalent for over $9 billion, marking one … High (80%)

View full analysis →

Financial Times 80% confidence